Boston Scientific Corp (BSX)vsCatheter Precision Inc. (VTAK)
BSX
Boston Scientific Corp
$69.78
+0.57%
HEALTHCARE · Cap: $101.28B
VTAK
Catheter Precision Inc.
$1.08
-6.09%
HEALTHCARE · Cap: $3.05M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 3345567% more annual revenue ($20.07B vs $600,000). BSX leads profitability with a 14.4% profit margin vs 0.0%. VTAK trades at a lower P/E of 0.1x. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
VTAK
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
+99.2%
Fair Value
$228.68
Current Price
$1.08
$227.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 128.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : VTAK
The strongest argument for VTAK centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : VTAK
The primary concerns for VTAK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a growth stock while VTAK is a hypergrowth play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.70 — expect wider price swings.
VTAK is growing revenue faster at 128.0% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 38/100) and 15.9% revenue growth. VTAK offers better value entry with a 99.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Catheter Precision Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?